Trial Profile

An Open-Label Extension Study Evaluating the Safety and Efficacy of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Encore Study)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADP 101 (Primary)
Indications Food hypersensitivity
Focus Adverse reactions
Acronyms The Encore Study
Sponsors Alladapt Immunotherapeutics

Most Recent Events

22 Mar 2024 Status changed from active, no longer recruiting to discontinued (sponsor's decision).
21 Dec 2022 Status changed from recruiting to active, no longer recruiting.
22 Jun 2022 According to an Alladapt Immunotherapeutics media release, the company announced the closing of a $119 million financing round led by Enavate Sciences; proceeds from this funding round will support the ongoing clinical development of ADP101

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com